Diabetes Obes Metab: SGLT2 inhibitors and all-cause mortality

In a recent study published in TheDiabetes Obesity and Metabolism, an authoritative journal in the field of metabolic endocrine diseases, the meta-analysis was designed to assess the effects of sodium-glucose co-transport protein 2 (SGLT2) inhibitors on all-cause mortality, as well as differences between different trials and molecular types.
researchers included randomized clinical trials of all treatments that lasted more than 52 weeks, recruiting at least 100 patients in each group and comparing SGLT2 inhibitors with any control or placebo.
Based on the inclusion criteria, the researchers selected 21 trials, with 39,593 SGLT2 inhibitors and 30,771 control users, with a treatment medium time of 104 weeks, and 2474 and 2298 deaths reported by the SGLT2 inhibitor group and the control group, respectively.
researchers did not find the relevant heterogeneity (I2-17%).
treatment with SGLT2 inhibitors can significantly reduce the total cause mortality rate (MH-OR (95% CI) is 0.86 (0.81-0.91), p.lt;0.00001).
, in randomized controlled trials, taking SGLT2 inhibitors reduced all-cause mortality in patients.
。